A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Sponsor
Janssen Research & Development, LLC
Study ID
NCT05236868
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Seltorexant — DRUG
    Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.

Study Details

The purpose of this study is to determine the absolute bioavailability of seltorexant in healthy participants following a single oral dose of seltorexant and an intravenous (IV) infusion dose of 14C-seltorexant.

Key Dates

Start date
Feb 3, 2022
Status verified
Apr 2025
Primary completion
Mar 1, 2022
Completion
Mar 1, 2022

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Seltorexant
    Participants will receive a single oral dose of seltorexant. At 2 hours after oral dosing, participants will receive 14C-seltorexant as an intravenous (IV) infusion over 15 minutes.

Primary Outcome Measure

Absolute Bioavailability [ Time Frame: Up to Day 4 ]

Related Studies